4th In Vivo Cell Engineering and Gene Editing Summit

Welcome to the 4th In Vivo Cell Engineering and Gene Editing Summit, the premier event dedicated to enhancing the next frontier of in vivo cell and gene approaches from research to clinic. This summit provides you with exclusive insights into the latest IND enabling data, regulatory and inter-governmental processes and requirements, best-in-class delivery technologies, cutting-edge innovations in editing and engineering and insights into effective clinical trial design from industry leaders including Capstan Therapeutics, Editas Medicine, Carisma Therapeutics, AbbVie, Intellia Therapeutics, Umoja Biopharma and many more!

The in vivo approach is revolutionizing the cell and gene space. These ground-breaking technologies promise more efficient, accessible and cost-effective therapies and paving the way for the future of cell and gene treatments. With leading companies entering the clinic and investments and collaborations unfolding, the potential of in vivo therapies to treat a variety of indications including oncology, genetic and rare diseases is now front and centre.

Gain exclusive access to ground-breaking discoveries and networking opportunities to propel your pipelines to new heights!


URLs:
Brochure: https://go.evvnt.com/2884100-0?pid=10018
Tickets: https://go.evvnt.com/2884100-1?pid=10018
Website: https://go.evvnt.com/2884100-2?pid=10018

Venue Details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States

Prices:
Drug Developer Pricing - Conference and Workshop Day: USD 4197.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic and Start-up Pricing - Conference and Workshop Day: USD 3597.00,
Academic and Start-up Pricing - Conference Only: USD 2599.00,
Service and Solution Providers - Conference and Workshop Day: USD 5097.00,
Service and Solution Providers - Conference Only: USD 3699.00

Speakers: Cecile Bauche, Founder and Chief Scientific Officer, Alaya.bio, Adrian Bot, Founding Chief Scientific Officer and Executive Vice President - Research and Development, Capstan Therapeutics, Delai Chen, Director - Nanoparticle Formulation, Beam Therapeutics Inc., Gilmore O'Neill, President and Chief Executive Officer, Editas Medicine, Michael Klichinsky, Co-Founder and Chief Scientific Officer, Carisma Therapeutics, Laura Green Director, Program Management, Umoja Biopharma, Daniel Getts, Chief Executive Officer, Myeloid Therapeutics, Robert Hofmeister, Chief Scientific Officer, Myeloid Therapeutics